STAT+: How Pfizer’s grand gene therapy ambitions crumbled
A decade ago, Pfizer began investing heavily in gene therapy, bringing in experimental treatments for…
Category: Pharma
.jpg)
STAT+: The state pharma’s targeting this election cycle
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Six questions about Medicare’s proposed plan to cover digital therapeutics
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
STAT+: A preview of Neurocrine’s muscarinic drug readout
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
A potential rival for Wegovy and Zepbound enters the fray
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a Viking obesity drug, Bausch Health’s bankruptcy denial, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Merck lays off workers amid rough pharma job market
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pfizer gene therapy reduced hemophilia bleeds, but questions remain
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for…
STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more
Top of the morning to you, and a fine one it is, despite the gray…
Contradictory coverage decisions in North Carolina
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare’s worst option
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight…
Four health care and biotech updates to stay on top of this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Express Scripts overcharging postal workers, Gilead’s AIDS drug price, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about an FDA rare disease innovation hub, fewer U.S. drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
Novo, Lilly shares sink due to concerns over competition
Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD…
Listen: JD Vance’s biotech ties, Cassava resignations, and insulin shortages
What relation does JD Vance have with Vivek Ramaswamy? Do pharma companies have a moral…
STAT+: Here come Medicare’s first negotiated drug prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
The biotech news stories you need to know today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Novartis hedges on when it might submit myelofibrosis drug for approval
LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the…
STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
It’s happy hour (for now) for Alnylam
Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and…
STAT+: A second Roche obesity drug shows promise in early studies
LONDON — Roche on Wednesday reported positive early data from another of the obesity drug…
Sen. Menendez’s conviction may cost pharma a key ally in Congress
A New York jury on Tuesday found Sen. Bob Menendez guilty on 16 counts for…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more
And so, another working week will soon draw to a close. Not a moment too…
Element Biosciences raises another massive round
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can you get satiety with GLP-1s without the nausea?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pfizer says it will advance once-daily GLP-1 pill after all
Pfizer said that it plans to advance a new once-a-day formulation of its experimental obesity…
STAT+: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down
Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drugmakers are losing crucial friends on Capitol Hill
WASHINGTON — Sen. Bob Menendez is the poster child for a pharmaceutical industry ally. He…
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 million last year to…
STAT+: Judge rules against Boehringer Ingelheim in pharma’s latest legal loss on Medicare negotiation
WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug…
STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a GSK vaccine deal, an Alzheimer’s drug approval, and more
Top of the morning to you, and a fine one it is. The skies are…
GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership
GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control…
STAT+: Pharmalittle: We’re reading about FTC probing Teva patents, a Moderna flu vaccine contract, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: We’re reading about indicted drug wholesalers, a gene therapy rejection, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry
The Food and Drug Administration’s power to make important regulatory decisions is in question after…